Using Technology to Reduce Youth Substance Use

Overview

The research project will focus on conducting a trial of whether a tailored SMS text-messaging intervention is efficacious in improving justice-involved youths' substance use or dual diagnosis treatment attendance and engagement.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2024

Detailed Description

The study will demonstrate how delivery of text messages for appointment reminders and motivational/coaching message to justice-involved youth and their caregivers will lead to greater youth substance use treatment attendance and engagement. The study will start with identifying the feasibility and acceptability of the SMS text-messaging intervention with community-supervised justice-involved youth. Then, the study will determine whether the tailored dyadic (youth and caregiver) SMS text-messaging intervention improves justice-involved youth substance use or dual diagnosis treatment attendance and engagement relative to standard of care (not receiving text messaging appointment reminders and motivational/coaching messages). Finally, the study will characterize patterns of key justice and behavioral health system-level factors that promote or hinder eventual adoption and sustainability of mHealth technology as a tool to improve treatment attendance for justice-involved youth.

Interventions

  • Behavioral: SMS Text Messaging
    • SMS text messaging intervention for a period of 90 days to remind of community-based substance use treatment appointments and to provide motivational texts.
  • Behavioral: Standard of Care Engagement Practices
    • Standard of care engagement practices, such as communicating with youth and caregivers, as needed, through texting but frequency of contact and content of messaging varies according to individual needs.

Arms, Groups and Cohorts

  • Experimental: Text-messaging
    • SMS text messaging intervention for a period of 90 days to remind of community-based substance use treatment appointments and to provide motivational texts.
  • Active Comparator: Standard of care engagement practices
    • Standard of care engagement practices, such as communicating with youth and caregivers, as needed, through texting but frequency of contact and content of messaging varies according to individual needs.

Clinical Trial Outcome Measures

Primary Measures

  • Treatment session attendance
    • Time Frame: 30 days post baseline
    • Proportion of treatment sessions attended
  • Treatment session attendance
    • Time Frame: 60 days post baseline
    • Proportion of treatment sessions attended
  • Treatment session attendance
    • Time Frame: 90 days post baseline
    • Proportion of treatment sessions attended
  • Treatment session attendance
    • Time Frame: 120 days post baseline
    • Proportion of treatment sessions attended
  • Treatment session attendance
    • Time Frame: 180 days post baseline
    • Proportion of treatment sessions attended

Secondary Measures

  • First treatment session initiation
    • Time Frame: 120 days post baseline
    • Proportion who attended first treatment session, as scheduled
  • First treatment session initiation
    • Time Frame: 180 days post baseline
    • Proportion who attended first treatment session, as scheduled

Participating in This Clinical Trial

Inclusion Criteria

  • English-speaking youth
  • Ages 13-18
  • Justice-involved while living in the community
  • Own a mobile phone or tablet
  • Are willing to send and receive text messages
  • Are referred to community-based substance use and/or mental health treatment

Exclusion Criteria

Gender Eligibility: All

Minimum Age: 13 Years

Maximum Age: 18 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of California, San Francisco
  • Collaborator
    • National Institute on Drug Abuse (NIDA)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Marina Tolou-Shams, PhD, Principal Investigator, University of California, San Francisco
  • Overall Contact(s)
    • Marina Tolou-Shams, PhD, 628-206-2212, marina.tolou-shams@ucsf.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.